PTEN and cancer: Based on the previous studies demonstrating that miR-425-mediated suppression of PTEN promotes cancer aggressiveness and is associated with tumorigenesis and malignancy in many cancers [29,30,31], we tested whether PAM- and PAM/TRAIL-treatment can downregulate the miR-425 transcription.